Postbiotica has signed a licensing and commercialising agreement with Candioli Pharma, a company leader in the pet-care market. The agreement foresees the exclusivity of the postbiotic ImmunoFOS® as an active ingredient to develop innovative nutraceuticals for pet...
In Equilibrio
Postbiotics represent an innovative therapeutic approach to prevent NEC
Necrotizing enterocolitis (NEC) primarily affects premature newborns, occurring in 7–10% of very low birth weight infants, from 2 weeks to 2 months of age, with an incidence inversely related to gestational age (Patel et al. 2015). It is associated with a mortality as...
The liver-gut axis: how the Dysbiosis is involved in NAFLD and NASH.
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients...
Postbiotics: the new bioactive compounds.
Gut bacteria depend fully on their host to provide the necessary nutrients that may promote microbiota growth. However, bacteria produce small molecular weight metabolites during their lifecycle; these compounds play a key role in regulating self-growth, development,...
Healthy Gut Microbiota for living healthy life
The human gut is the habitat to trillions of microbial cells with over 1,000 diverse microbial species that contribute to the primary functions of the gastrointestinal tract, including nutrition and defense. On the other hand, the gastrointestinal tract mucosa...
MyStartBCN: a big victory for Postbiotica
Postbiotica, represented by Francesca Algieri, won the first edition of the My Start BCN contest and has been rewarded by the President of the Chamber of Commerce, Igor Garzesi. Postbiotica has impressed the jury for the development of new metabolities derivated from...
Postbiotica wins BIOUPPER
Postbiotica has presented the new technology to modulate the production of bacterial metabolites, called Postbiotics. Postbiotica has been selected among 151 projects by Bioupper. Bioupper is a training and acceleration platform and converts and enhances he best ideas...
From research to business
Maria Rescigno, professor and entrepreneur, co-founder of POSTBIOTICA, an innovative biopharmaceutical StartUp winner of the "MYSTART BCN" competition, is interviewed by "Italiani Anywhere".